|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2005
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
1 Dept of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, and 2 Dept of Thoracic Medicine, University Hospital of Heraklion, Crete, Greece.
CORRESPONDENCE: D. Bouros, Medical School, Democritus University of Thrace, Alexandroupolis 68100, Greece. Fax: 30 2551076106. E-mail: bouros{at}med.duth.gr
Keywords: Idiopathic pulmonary fibrosis, interstitial lung diseases, therapy
Received: December 18, 2004
Accepted April 4, 2005
Idiopathic pulmonary fibrosis (IPF) is a lethal form of idiopathic diffuse lung disorders for which no current treatment is effective. The aim of the present study was to systematically review the current status and novel therapies of IPF, with emphasis on controlled trials.
The studies selected included randomised controlled trials using drugs alone and/or in combination for the treatment of adults with IPF and meta-analyses, published in English. Abstracts of identified articles were retrieved and articles possibly fulfilling inclusion criteria were retrieved in full. Two reviewers independently assessed trial quality if there were any included studies. Data quality was based on place of publication and relevance to clinical care.
There is a lack of good-quality studies regarding the effectiveness of the most used drugs, including corticosteroids and noncorticosteroid immunosuppressive agents. Oral corticosteroids are the usual treatment. Other therapies either alone or in combination with corticosteroids are widely used, including azathioprine, cyclophosphamide and colchicine. Interestingly, clinical trials with novel drugs, mainly antifibrotic, anticytokine and immunoregulatory, are currently being investigated in various trial phases.
In conclusion, at present, there are no evidence-based therapies for idiopathic pulmonary fibrosis. Further controlled studies are warranted to improve the evidence base for clinical practice.
This article has been cited by other articles:
|
|
 |
|
  V. Martins, S. S. Valenca, F. A. Farias-Filho, R. Molinaro, R. L. Simoes, T. P. T. Ferreira, P. M. R. e Silva, C. M. Hogaboam, S. L. Kunkel, I. M. Fierro, et al. ATLa, an Aspirin-Triggered Lipoxin A4 Synthetic Analog, Prevents the Inflammatory and Fibrotic Effects of Bleomycin-Induced Pulmonary Fibrosis J. Immunol., May 1, 2009; 182(9): 5374 - 5381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Keane The role of chemokines and cytokines in lung fibrosis Eur. Respir. Rev., December 1, 2008; 17(109): 151 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Papadopoulos, G. Pitsiou, T. D. Karamitsos, H. I. Karvounis, T. Kontakiotis, G. Giannakoulas, G. K. Efthimiadis, P. Argyropoulou, G. E. Parharidis, and D. Bouros Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic study Eur. Respir. J., April 1, 2008; 31(4): 701 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Myllarniemi, P. Lindholm, M. J. Ryynanen, C. R. Kliment, K. Salmenkivi, J. Keski-Oja, V. L. Kinnula, T. D. Oury, and K. Koli Gremlin-mediated Decrease in Bone Morphogenetic Protein Signaling Promotes Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., February 1, 2008; 177(3): 321 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Azuma, Y. Nishioka, Y. Aono, M. Inayama, H. Makino, J. Kishi, M. Shono, K. Kinoshita, H. Uehara, F. Ogushi, et al. Role of {alpha}1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1243 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Noth and F. J. Martinez Recent Advances in Idiopathic Pulmonary Fibrosis Chest, August 1, 2007; 132(2): 637 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Kuschner, J.-L. Andreu, L. Silva, K. M. Sullivan, P. A. McSweeney, R. A. Nash, D. P. Tashkin, P. J. Clements, and M. D. Roth Cyclophosphamide in Scleroderma Lung Disease N. Engl. J. Med., September 14, 2006; 355(11): 1173 - 1174. [Full Text] [PDF]
|
|
|
|
 |
|
 S J Bourke Interstitial lung disease: progress and problems. Postgrad. Med. J., August 1, 2006; 82(970): 494 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Wells Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur. Respir. J., April 1, 2006; 27(4): 664 - 666. [Full Text] [PDF]
|
|
|
|
|
|
G. Raghu, S. T.-Y. Yang, C. Spada, J. Hayes, and C. A. Pellegrini Sole Treatment of Acid Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: A Case Series Chest, March 1, 2006; 129(3): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Martinez Idiopathic Interstitial Pneumonias: Usual Interstitial Pneumonia versus Nonspecific Interstitial Pneumonia. Proceedings of the ATS, January 1, 2006; 3(1): 81 - 95. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |